NCT07474558 2026-03-16
SCARLET-ICE
Jules Bordet Institute
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT04829604 2026-03-09
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Phase 2 Active not recruiting
NCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT07052760 2025-10-10
Imaging of Solid Tumors Using DLL3 SPECT
University of California, San Francisco
Phase EARLY_PHASE1 Not yet recruiting
NCT05011188 2025-08-27
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1/2 Active not recruiting
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT03255070 2024-02-01
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
Phase 1 Completed
NCT01605318 2024-01-24
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT03489525 2022-03-28
MEDI2228
MedImmune LLC
Phase 1 Completed
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn
NCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT01671813 2013-07-25
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn